InFoods® IBS Commercial Progress: Medicare-related test orders increased 120% in September 2026 compared to August, with growing physician participation and repeat ordering activityInFoods® IBS update: 100% of all
Fiscal 2026 fourth quarter net sales increased approximately 17% compared to the fourth quarter of fiscal 2025Full-year net loss improved by approximately 24% to approximately $3.8 millionInFoods IBS update: 100% of all
Financing priced at $1.60 with no warrants or discountB. Riley Principal Capital and B. Riley executives, as well as Biomerica's CEO and all members of Biomerica’s Board of Directors participated in the
IRVINE, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ:BMRA), a developer and manufacturer of diagnostic test systems and CDMO services provider, today announced it has entered into a Master Services
Veteran finance and operations leader brings more than 20 years of experience across public companies and high-growth organizations
ConsumerDirect Inc., an industry leader in helping consumers manage their credit,
IRVINE, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ:BMRA), a global biomedical technology company focused on innovative diagnostic-guided therapies, today announced that an abstract evaluating
The Medicare Administrative Contractor (MAC) responsible for processing inFoods® IBS claims has confirmed to Biomerica's certified laboratory partner that the test will be reviewed on an individual, claim-by-claim
— Represents Biomerica's First Commercial Entry into the Canadian Market for its Precision, Diagnostic-Guided Therapy — Canada Has One of the Highest IBS Prevalence Rates in the World — an Estimated 18% vs. 11% Globally
IRVINE, Calif., April 13, 2026 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ:BMRA), ("Biomerica" or the "Company") a global provider of advanced medical diagnostic and therapeutic products today reported financial
First Commercial Order by Large Lab Chain: Biomerica has received its first commercial order for Hp Detect™, from one of the largest clinical laboratory chains operating across Europe.Strategic Account: This new
UK Market Entry: MHRA registration authorizes hp+detect™ for commercial sale in Great BritainActive Commercialization: Biomerica is in active discussions with UK partners to access the diagnostic laboratory market
Key Highlights Responder Analysis: 59.4% of patients achieved ≥30% reduction in abdominal pain; 68.1% achieved ≥30% reduction in bloating—using the FDA-recognized responder endpoint consistent with the Company's
Approval Marks Biomerica's Strategic Entry into Southeast Asia's Rapidly Growing Healthcare MarketSimple, FDA-Cleared At-Home Test Detects an Early Warning Sign of Colorectal Cancer in Minutes IRVINE, Calif., Feb. 18,
Operating Expenses Decline 4% Year-to-DateBalance Sheet Strengthens and Working Capital Improves by 14.7% IRVINE, Calif., Jan. 14, 2026 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ:BMRA), (the "Company") a global
CMS is the single largest payer for healthcare in the United States, with Medicare responsible for approximately 21% of total healthcare expenditure.The $300 rate will apply to claims approved and paid by Medicare with
